Form 4: Trevi Therapeutics Director Receives Stock Option Grant

Director Edward T. Mathers was granted 35,000 nonstatutory stock options in Trevi Therapeutics, Inc.

Summary

• Director Edward T. Mathers received a grant of 35,000 nonstatutory stock options on June 3, 2026.
• The options have an exercise price of $13.45 per share.
• The options are scheduled to fully vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these stock options.

Risks

• Market price volatility affecting the value of the granted options.
• Dependence on continued service as a director for the vesting of the options.

Future Outlook

The options vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for small-cap biotechnology companies.
• Vesting schedules tied to annual meetings are common industry practice to align director tenure with shareholder cycles.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on the earlier of June 3, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Trevi Therapeutics, TRVI, Form 4, Insider Trading, Stock Options, Director Compensation